Literature DB >> 25366122

Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units.

Anne-Claire Toffart1, Xavier Dhalluin, Nicolas Girard, Christos Chouaid, Clarisse Audigier-Valette, Michaël Duruisseaux, Bertrand Mennecier, Antoine Parrot, Pierre Fournel, Denis Moro-Sibilot, Jean-François Timsit.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25366122     DOI： 10.1007/s00134-014-3535-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  5 in total

1.  Use of intensive care in patients with nonresectable lung cancer.

Authors:  Anne-Claire Toffart; Clémence Minet; Bruno Raynard; Carole Schwebel; Rebecca Hamidfar-Roy; Samia Diab; Sébastien Quetant; Denis Moro-Sibilot; Elie Azoulay; Jean-François Timsit
Journal:  Chest       Date:  2010-07-15       Impact factor: 9.410

2.  Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation.

Authors:  Wouter H van Geffen; Thijo J N Hiltermann; Harry J M Groen
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

3.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

4.  Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer.

Authors:  Hee Kyung Ahn; Kyeongman Jeon; Hongseok Yoo; Boram Han; Su Jin Lee; Hyeyon Park; Min Ji Lee; Sang Yun Ha; Joung Ho Han; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

5.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245
  5 in total
  6 in total

Review 1.  Focus on immunocompromised patients.

Authors:  Michael Darmon; Otavio T Ranzani; Elie Azoulay
Journal:  Intensive Care Med       Date:  2017-06-09       Impact factor: 17.440

2.  Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit.

Authors:  Chun-Ru Chien; Hung-Jen Chen
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study.

Authors:  Chia-I Shen; Shan-Yao Yang; Hwa-Yen Chiu; Wei-Chih Chen; Wen-Kuang Yu; Kuang-Yao Yang
Journal:  BMC Pulm Med       Date:  2022-06-24       Impact factor: 3.320

Review 4.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

5.  Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation.

Authors:  How-Yang Tseng; Yi-Cheng Shen; Yen-Sung Lin; Chih-Yen Tu; Hung-Jen Chen
Journal:  Thorac Cancer       Date:  2020-08-06       Impact factor: 3.500

6.  Patterns of ICU admissions and outcomes in patients with solid malignancies over the revolution of cancer treatment.

Authors:  Clara Vigneron; Julien Charpentier; Sandrine Valade; Jérôme Alexandre; Samy Chelabi; Lola-Jade Palmieri; Nathalie Franck; Valérie Laurence; Jean-Paul Mira; Matthieu Jamme; Frédéric Pène
Journal:  Ann Intensive Care       Date:  2021-12-24       Impact factor: 6.925
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.